Semaglutide

Overview

What is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone your gut releases after eating that signals fullness, slows gastric emptying, and supports glucose regulation. In a medical weight management program it is prescribed after physician review and paired with nutrition, resistance training, and protein targets to protect lean mass.

Mechanism

How it works

By activating GLP-1 receptors in the brain and gut, semaglutide reduces appetite and food-seeking signals, slows stomach emptying so meals feel satisfying for longer, and improves glucose-dependent insulin response. The result is a lower spontaneous calorie intake without the constant hunger that undermines most weight loss attempts.

Wellness support

Potential wellness support areas

These areas are commonly discussed within wellness-focused protocols. They are educational statements, not medical claims or guarantees of outcome.

• Physician-directed weight management
• Appetite and craving regulation
• Glycemic and cardiometabolic markers
• Used alongside nutrition and strength training to preserve lean mass

Administration

Format & dosing

A once-weekly subcutaneous injection using a slow titration schedule that starts low and increases only as tolerated. Your physician sets the starting dose, the escalation pace, and the maintenance dose based on response and side effects.

Labs & monitoring

Labs, testing & monitoring

Your physician determines the final testing requirements for Semaglutide after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.

Commonly reviewed at baseline

• A1c and fasting glucose
• Comprehensive metabolic panel (CMP)
• Lipid panel
• Thyroid panel (TSH)
• Pregnancy status where applicable

Follow-up & monitoring

Weight, blood pressure, and tolerance are reviewed at each titration step, with A1c and a metabolic panel commonly repeated at 12 weeks.

Who may not be a candidate

• Pregnancy or nursing
• Active malignancy without oncology clearance
• Known hypersensitivity to the preparation
• Personal or family history of medullary thyroid carcinoma or MEN2
• History of pancreatitis
• Active gastroparesis

Medication interactions

Your physician reviews all prescriptions, supplements, and over-the-counter medications during intake before anything is prescribed.

Safety

Safety & considerations

Compounded semaglutide is not an FDA-approved product and is prepared for an individual patient pursuant to a valid prescription. Nausea, reflux, constipation, and early fullness are the most common effects and usually ease with slower titration. Not appropriate with a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, active gastroparesis, or during pregnancy or nursing.

Regulatory status: Compounded. Evidence level: Established. Eligibility, dosing, laboratory requirements, and follow-up care are determined exclusively by a licensed physician after review of your history.